The results exhibited that ACSL1, BCL2, c-MYC, and CDKN1A mRNA and protein expressions were increased in PRADX overexpressed tumor cells, in contrast to the PRADX overexpressed plus WP1066-treated group (Figures 5A, B), indicating PRADX-induced activation of STAT3 pathway and its downstream genes’ expression, including ACSL1. The gene discussed is BCL2; the disease is neoplasm.